Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Third party research

Vitrolife: Analyst - ABG

Vitrolife

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
SEK 4.3bn impairment charge of Igenomix
1.6% beat on preliminary Q4 adj EBITDA
Minor positive earnings revisions expected


Impairment charge of Igenomix

Vitrolife will make a SEK 4.3bn non-cash impairment charge related to the Igenomix acquisition in Q4, equal to 31% of the goodwill and other intangible assets related to Igenomix. In the Igenomix transaction, Vitrolife paid with a combination of shares and cash, and as the share price of Vitrollife appreciated during the period from signing until issuance of the new shares, the total purchase price increased from SEK 11.6bn to SEK 14.7bn, creating higher goodwill than initially anticipated. The slowdown seen in the Genetic Services business in 2023, and in combination with a higher WACC used for the impairment test, has made it more challenging to for Vitrolife to justify the book value of the intangible assets related to the acquisition. The Genetic Services business remains a key component of Vitrolife's strategy and actions are being implemented to improve the sales growth and profitability of the business.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.